Clinical Trials Browser

Phase 2 × Interventional × Epoetin Alfa × Clear all

NCT05564390 2026-05-26

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

Phase 2 Recruiting

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute

NCT00049348 2023-06-15

Chemotherapy and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer

Phase 2 Completed

Gastrointestinal

Pancreatic Neoplasms

NCT00624312 2021-08-06

Procrit Versus Placebo to Determine Efficacy in Pre-Operative Major Surgical Oncology Operations

Phase 2 Withdrawn

Neoplasms

NCT00481624 2018-03-05

Procrit

Phase 2 Withdrawn

Classical hematology

Anemia

NCT01467115 2017-05-09

DREXNECK

Phase 2 Completed

Head and Neck Neoplasms

NCT00416624 2017-02-10

Epoetin Alfa or Darbepoetin Alfa in Treating Patients With Anemia Caused by Chemotherapy

Phase 2 Completed

239 enrolled 23 charts

Classical hematologyDermatologicLymphoidOther hematologic neoplasmOther neoplasmPlasma cell

Immunoglobulin Light-chain Amyloidosis, Anemia, Burkitt Lymphoma, Hodgkin Disease, Immunoblastic Lymphadenopathy, Leukemia, Leukemia, Hairy Cell, Leukemia, Mast-Cell, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Waldenstrom Macroglobulinemia, Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, Mycosis Fungoides, Precancerous Conditions, Sezary Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Biphenotypic, Acute, Leukemia, Prolymphocytic, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Leukemia, Large Granular Lymphocytic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Neoplasms, Plasma Cell, Lymphoma, Extranodal NK-T-Cell

NCT00267007 2014-06-04

A Study to Investigate the Neuroprotective Effect of PROCRIT (Epoetin Alfa) Versus Placebo in Cancer Patients Who Develop Chemotherapy-induced Peripheral Neuropathy

Phase 2 Terminated

32 enrolled 9 charts

Neoplasms, Peripheral Nervous System Diseases

NCT00386152 2013-07-19

A Study Comparing Two Different PROCRIT Doses to a Dose of ARANESP in Anemic Cancer Patients Receiving Chemotherapy

Phase 2 Terminated

235 enrolled 13 charts

Classical hematology

Anemia, Neoplasms

NCT00053001 2013-06-26

Thalidomide and Epoetin Alfa in Treating Anemia in Patients With Myelodysplastic Syndrome

Phase 2 Completed

Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative

NCT00255749 2012-10-04

Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy for Cancer

Phase 2 Completed

Classical hematologyDermatologicLymphoidOther hematologic neoplasmOther neoplasmPlasma cell

Immunoglobulin Light-chain Amyloidosis, Anemia, Burkitt Lymphoma, Hodgkin Disease, Immunoblastic Lymphadenopathy, Leukemia, Leukemia, Hairy Cell, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Waldenstrom Macroglobulinemia, Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, Mycosis Fungoides, Precancerous Conditions, Sezary Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Leukemia, Large Granular Lymphocytic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Neoplasms, Plasma Cell

NCT00004914 2012-06-06

Exercise Plus Epoetin Alfa in Treating Cancer Patients Who Have Anemia-Related Fatigue

Phase 2 Completed

Classical hematology

Anemia, Fatigue

NCT00210600 2011-06-10

Early and Standard Intervention With 120,000 Units of PROCRIT (Epoetin Alfa) Every Three Weeks in Patients Receiving Chemotherapy

Phase 2 Completed

Classical hematology

Anemia

NCT00210834 2011-06-10

An Efficacy and Safety Study of Epoetin Alfa (PROCRIT) Initiated at 40,000 Units Every Week Versus 80,000 Units Every Two Weeks in Anemic Patients With Cancer Receiving Chemotherapy.

Phase 2 Completed

Classical hematology

Anemia

NCT00337948 2011-06-10

An Efficacy and Safety Study of PROCRIT (Epoetin Alfa) in Cancer Patients Receiving Chemotherapy Every Week or Every Four Weeks

Phase 2 Completed

Classical hematology

Anemia, Neoplasms

NCT00338416 2011-06-10

An Efficacy and Safety Study of PROCRIT (Epoetin Alfa) in Cancer Patients Receiving Chemotherapy Every Three Weeks

Phase 2 Completed

Classical hematology

Anemia, Neoplasms

NCT00269984 2011-06-08

A Study to Determine the Safety and Effectiveness of Epoetin Alfa Versus Placebo in Patients With Persistent Anemia Caused by Advanced Cancer

Phase 2 Completed

Classical hematology

Anemia, Neoplasms

NCT00338299 2011-05-23

Alternate Dosing of PROCRIT (Epoetin Alfa) in Patients With Cancer and Chemotherapy Induced Anemia

Phase 2 Completed

Classical hematology

Anemia

NCT00266617 2011-05-18

A Study to Evaluate the Safety and Effectiveness of Epoetin Alfa in Patients With Anemia as a Result of Advanced Cancer and Treatment With Aggressive Chemotherapy

Phase 2 Completed

Classical hematology

Anemia, Neoplasms

NCT00269997 2011-05-18

A Study to Evaluate the Safety and Effectiveness of Epoetin Alfa Versus Placebo in Patients With Persistent Anemia as a Result of Cancer Treatment With Cisplatin, a Platinum-containing Chemotherapy Drug

Phase 2 Completed

Classical hematology

Anemia, Neoplasms

NCT00270049 2011-05-18

Epoetin Alfa for the Treatment of Anemia Resulting From Chronic Lymphocytic Leukemia

Phase 2 Completed

Classical hematologyLymphoidOther hematologic neoplasm

Anemia, Leukemia, Leukemia, Lymphoid, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell

NCT00306267 2011-05-18

A Study of PROCRIT (Epoetin Alfa) 80,000 Units (U) Once Every Four Weeks (Q4W) vs. 40,000 U Once Every Two Weeks (Q2W) in Cancer Patients Not Receiving Chemotherapy

Phase 2 Terminated

Classical hematology

Anemia, Neoplasms

NCT00388336 2011-05-18

PROCRIT (Epoetin Alfa) 60,000 Units Administered Once Every Two Weeks in Anemic Cancer Patients Who Are Not Receiving Chemotherapy or Radiation Therapy

Phase 2 Completed

Classical hematology

Anemia, Neoplasms